Fond de dotation AGIR pour les maladies chroniques Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2018
NCT03545997
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Fond de dotation AGIR pour les maladies chroniques

Active Ingredients

Drugs in Phase 3 Trials (1)

montelukast (singulair) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Apnea (Phase 3)

Sleep Apnea, Obstructive (Phase 3)

Sleep Apnea Syndromes (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1